Applied DNA to Report First Quarter Fiscal 2023 Financial Results and Host Investor Conference Call and Webcast on Thursday, February 9, 2023

Rhea-AI Summary

Applied DNA Sciences (NASDAQ: APDN) will release its financial results for the quarter ending December 31, 2022, after market close on February 9, 2023. A conference call is scheduled for 4:30 p.m. ET to discuss the results and answer questions from investors. Interested parties can participate via domestic and international dial-in numbers or by accessing a live webcast at this link. A replay will be available for one week following the call. Applied DNA focuses on DNA technologies for therapeutics, diagnostics, and supply chain security.

Positive

• Upcoming release of quarterly financial results, which could provide insight into company performance.

Negative

• None.

STONY BROOK, N.Y.--(BUSINESS WIRE)-- Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”), a leader in polymerase chain reaction ("PCR")-based technologies, today announced that it will release financial results for the three months ended December 31, 2022, after the market closes on Thursday, February 9, 2023. The Company will host a conference call for the investment community to discuss its results and answer questions at 4:30 p.m. ET.

Date & Time: Thursday, February 9 @ 4:30 p.m. ET

Dial In (ask to be joined into the Applied DNA Sciences call):

• Domestic callers (toll free): 844-887-9402
• Canadian callers (toll free): 866-605-3852
• International callers: 412-317-6798
• Live webcast: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gZ93PCbr

A telephonic replay of the conference call will be available for 1 week following the conclusion of the live call:

• Replay for domestic callers (toll free): 877-344-7529, replay access code 2079390
• Replay for Canadian callers: 855-669-9658, replay access code 2079390

An archived webcast replay of the conference call will be available for 1 year following the conclusion of the live call: https://event.choruscall.com/mediaframe/webcast.html?webcastid=gZ93PCbr

An accompanying slide presentation will be embedded in the webcast (live and replay) and can also be accessed in the ‘Company Events’ section of the ‘News & Events’ tab of the Applied DNA investor relations website at https://investors.adnas.com/.

About Applied DNA Sciences

Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under the ticker symbol 'APPDW.'

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005522/en/

Investor Relations: Sanjay M. Hurry, 917-733-5573, sanjay.hurry@adnas.com

Web: www.adnas.com

Twitter: @APDN

Source: Applied DNA Sciences, Inc.

FAQ

When will Applied DNA Sciences announce its financial results for Q1 2023?

Applied DNA Sciences will announce its financial results for Q1 2023 on February 9, 2023, after market close.

What time is the conference call for Applied DNA Sciences on February 9, 2023?

The conference call for Applied DNA Sciences is scheduled for 4:30 p.m. ET on February 9, 2023.

How can I listen to the Applied DNA Sciences conference call?

You can listen to the Applied DNA Sciences conference call via a live webcast or by dialing in at the provided numbers for domestic or international callers.

Where can I find the financial results of Applied DNA Sciences after announcement?

The financial results will be available on the Applied DNA Sciences investor relations website following the announcement.